Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091019 · ClinicalTrials.gov registry record
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07091019 is a clinical trial that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 1,000 participants.
The verdict
NCT07091019 is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Interventions
- OTHER TKIs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2033-04-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091019
The ClinicalTrials.gov registry entry for NCT07091019 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TKIs is the first listed.
NCT07091019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07091019 about?
NCT07091019 is a clinical study titled "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy". This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and ...
What is the current status of trial NCT07091019?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-12-17. Estimated completion is 2033-04-20.
What interventions are being tested in trial NCT07091019?
The interventions under investigation include: TKIs (OTHER).
Who is sponsoring clinical trial NCT07091019?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.